XTL Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . XTL Biopharmaceuticals Ltd
XTLB Stock  USD 1.28  0.03  2.40%   
XTL Biopharmaceutica financial statements provide useful quarterly and yearly information to potential XTL Biopharmaceuticals Ltd investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on XTL Biopharmaceutica financial statements helps investors assess XTL Biopharmaceutica's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting XTL Biopharmaceutica's valuation are summarized below:
Gross Profit
46 K
Quarterly Earnings Growth
(0.76)
Market Capitalization
11.3 M
Enterprise Value Revenue
60.1911
Revenue
46 K
We have found one hundred twenty available fundamental gauges for XTL Biopharmaceuticals, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of XTL Biopharmaceuticals prevalent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself for the next two years. The current year's Market Cap is expected to grow to about 6.2 M. The current year's Enterprise Value is expected to grow to about 3.5 M

XTL Biopharmaceutica Total Revenue

0.0

Check XTL Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XTL Biopharmaceutica's main balance sheet or income statement drivers, such as Other Operating Expenses of 654.1 K, Research Development of 26.5 K or Total Operating Expenses of 654.1 K, as well as many indicators such as Price To Sales Ratio of 0.15, Dividend Yield of 0.0 or PTB Ratio of 2.17. XTL financial statements analysis is a perfect complement when working with XTL Biopharmaceutica Valuation or Volatility modules.
  
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.

XTL Biopharmaceutica Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.1 M2.2 M8.7 M
Slightly volatile
Total Stockholder Equity1.9 M2 M7.6 M
Slightly volatile
Common Stock Shares Outstanding658 M626.6 M221 M
Slightly volatile
Liabilities And Stockholders Equity2.1 M2.2 M8.7 M
Slightly volatile
Other Stockholder Equity148.4 M168.3 M141.4 M
Slightly volatile
Total Liabilities176.1 K185.4 K917.3 K
Slightly volatile
Other Current Liabilities175.3 K184.5 K404.7 K
Slightly volatile
Total Current Liabilities176.1 K185.4 K646.2 K
Slightly volatile
Other Liabilities1.3 M1.2 M1.4 M
Pretty Stable
Accounts Payable855900303.4 K
Slightly volatile
Cash1.2 M1.3 M2.5 M
Pretty Stable
Non Current Assets Total324.9 K342 K1.4 M
Slightly volatile
Cash And Short Term Investments1.7 M1.8 M5.1 M
Slightly volatile
Net Receivables24.8 K26.1 K115.9 K
Slightly volatile
Common Stock Total Equity15.9 M15.2 M10 M
Slightly volatile
Short Term Investments517.3 K544.5 K2.6 M
Slightly volatile
Other Current Assets68 K36 K77.8 K
Pretty Stable
Property Plant And Equipment Gross1.7 K1.8 K67.7 K
Slightly volatile
Total Current Assets1.7 M1.8 M5.3 M
Slightly volatile
Common Stock17 M16.2 M10.4 M
Slightly volatile
Property Plant Equipment85590079.7 K
Slightly volatile
Intangible Assets324.9 K342 K931.9 K
Slightly volatile
Current Deferred Revenue29.9 K31.5 K57.2 K
Slightly volatile
Short Term Debt1 M578.7 K742.6 K
Slightly volatile
Short and Long Term Debt Total904.6 K952.2 K1.2 M
Slightly volatile
Net Tangible Assets4.6 M4.2 M4 M
Slightly volatile
Capital Surpluse119 M132.9 M145.4 M
Slightly volatile
Net Invested Capital1.9 M2 M4.1 M
Very volatile
Net Working Capital1.6 M1.7 M5.1 M
Slightly volatile
Capital Stock15 M16.2 M13.7 M
Slightly volatile

XTL Biopharmaceutica Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses654.1 K688.5 K2.4 M
Slightly volatile
Research Development26.5 K27.9 K813.9 K
Slightly volatile
Total Operating Expenses654.1 K688.5 K2.3 M
Slightly volatile
Depreciation And Amortization85590091.1 K
Slightly volatile
Selling General Administrative627.6 K660.6 K2 M
Slightly volatile
Selling And Marketing Expenses920.8 K843.3 K736.7 K
Pretty Stable
Non Recurring1.1 M763.2 K1.1 M
Slightly volatile

XTL Biopharmaceutica Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.9 M1.9 M2.5 M
Slightly volatile
End Period Cash Flow1.2 M1.3 M2.5 M
Pretty Stable
Sale Purchase Of Stock3.2 M5.6 M3.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.150.160.2465
Slightly volatile
PTB Ratio2.172.070.4408
Slightly volatile
Days Sales Outstanding21.2122.3327.804
Slightly volatile
Book Value Per Share0.00450.00470.1688
Slightly volatile
Capex To Depreciation8.918.496.4786
Slightly volatile
PB Ratio2.172.070.4408
Slightly volatile
Inventory Turnover0.00.00.3725
Slightly volatile
Days Of Inventory On Hand18.1 M17.2 M14.2 M
Slightly volatile
Payables Turnover1.0E-41.0E-40.2209
Slightly volatile
Sales General And Administrative To Revenue1.680.961.1524
Slightly volatile
Research And Ddevelopement To Revenue0.05210.05490.2842
Slightly volatile
Capex To Revenue0.03540.03190.0433
Slightly volatile
Cash Per Share0.0040.00420.0717
Slightly volatile
Days Payables Outstanding4.4 M4.2 M3.4 M
Slightly volatile
Intangibles To Total Assets0.180.15660.1501
Pretty Stable
Current Ratio7.988.9413.1404
Slightly volatile
Tangible Book Value Per Share0.00370.00390.1652
Slightly volatile
Receivables Turnover17.7716.9216.279
Slightly volatile
Shareholders Equity Per Share0.00450.00470.1592
Slightly volatile
Capex Per Share0.00.03.0E-4
Slightly volatile
Revenue Per Share0.01160.01220.0173
Slightly volatile
Interest Debt Per Share1.0E-41.0E-41.0E-4
Slightly volatile
Graham Number0.01830.01060.0291
Slightly volatile
Operating Cycle18.1 M17.2 M14.2 M
Slightly volatile
Price Book Value Ratio2.172.070.4408
Slightly volatile
Days Of Payables Outstanding4.4 M4.2 M3.4 M
Slightly volatile
Company Equity Multiplier1.191.261.2021
Pretty Stable
Quick Ratio7.898.9413.0105
Slightly volatile
Net Income Per E B T0.00110.00120.3536
Slightly volatile
Cash Ratio4.746.127.5644
Slightly volatile
Days Of Inventory Outstanding18.1 M17.2 M14.2 M
Slightly volatile
Days Of Sales Outstanding21.2122.3327.804
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.90.9945
Slightly volatile
Price To Book Ratio2.172.070.4408
Slightly volatile
Fixed Asset Turnover24.4834.9532.2804
Slightly volatile
Price Sales Ratio0.150.160.2465
Slightly volatile
Asset Turnover0.290.270.2572
Slightly volatile
Gross Profit Margin0.430.620.6152
Slightly volatile
Price Fair Value2.172.070.4408
Slightly volatile

XTL Biopharmaceutica Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.2 M5.9 M1.3 M
Slightly volatile

XTL Fundamental Market Drivers

Cash And Short Term Investments2 M

XTL Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About XTL Biopharmaceutica Financial Statements

XTL Biopharmaceutica stakeholders use historical fundamental indicators, such as XTL Biopharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in XTL Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on XTL Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XTL Biopharmaceuticals Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue31.5 K29.9 K
Cost Of Revenue 900.00  855.00 
Stock Based Compensation To Revenue(0.03)(0.03)
Sales General And Administrative To Revenue 0.96  1.68 
Research And Ddevelopement To Revenue 0.05  0.05 
Capex To Revenue 0.03  0.04 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(1.10)(1.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:
How To Invest In XTL
Details
Is XTL Stock a good investment?
Details
What is XTL Biopharmaceutica's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
(0.20)
Return On Assets
(0.16)
Return On Equity
(0.26)
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY